FR13C0035I1 - - Google Patents

Info

Publication number
FR13C0035I1
FR13C0035I1 FR13C0035C FR13C0035I1 FR 13C0035 I1 FR13C0035 I1 FR 13C0035I1 FR 13C0035 C FR13C0035 C FR 13C0035C FR 13C0035 I1 FR13C0035 I1 FR 13C0035I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FR13C0035I1 publication Critical patent/FR13C0035I1/fr
Application granted granted Critical
Publication of FR13C0035I2 publication Critical patent/FR13C0035I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
FR13C0035C 2003-08-05 2013-07-04 Nouveaux derives d'insuline Active FR13C0035I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200301129 2003-08-05
US49545103P 2003-08-14 2003-08-14
EP04739008A EP1660531A2 (en) 2003-08-05 2004-07-22 Novel insulin derivatives

Publications (2)

Publication Number Publication Date
FR13C0035I1 true FR13C0035I1 (hr) 2013-08-09
FR13C0035I2 FR13C0035I2 (fr) 2014-03-07

Family

ID=34117520

Family Applications (2)

Application Number Title Priority Date Filing Date
FR13C0035C Active FR13C0035I2 (fr) 2003-08-05 2013-07-04 Nouveaux derives d'insuline
FR13C0038C Active FR13C0038I1 (fr) 2003-08-05 2013-07-05 Nouveaux derives d'insuline

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR13C0038C Active FR13C0038I1 (fr) 2003-08-05 2013-07-05 Nouveaux derives d'insuline

Country Status (18)

Country Link
US (3) US7615532B2 (hr)
EP (3) EP2264065B1 (hr)
JP (1) JP4463814B2 (hr)
KR (1) KR101159559B1 (hr)
AU (2) AU2004261353B2 (hr)
BE (2) BE2013C035I2 (hr)
BR (1) BRPI0413276B8 (hr)
CA (1) CA2531988C (hr)
CY (3) CY1113850T1 (hr)
FR (2) FR13C0035I2 (hr)
HU (1) HUS1300033I1 (hr)
IL (1) IL172980A (hr)
LU (2) LU92213I2 (hr)
MX (1) MXPA06001283A (hr)
NO (3) NO340925B1 (hr)
PL (1) PL2107069T3 (hr)
RU (1) RU2518460C2 (hr)
WO (1) WO2005012347A2 (hr)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2328579T3 (es) * 2003-07-25 2009-11-16 Conjuchem Biotechnologies Inc. Derivados de insulina de larga duracion y procedimientos asociados.
EP2264065B1 (en) 2003-08-05 2017-03-08 Novo Nordisk A/S Novel insulin derivatives
EP2256130B1 (en) 2005-02-02 2013-09-25 Novo Nordisk A/S Novel insulin derivatives
JP5410020B2 (ja) 2005-02-02 2014-02-05 ノヴォ ノルディスク アー／エス インスリン誘導体
CN101389650B (zh) * 2005-12-28 2012-10-10 诺沃-诺迪斯克有限公司 包含酰化胰岛素和锌的组合物以及制备所述组合物的方法
DE602007009496D1 (de) * 2006-02-27 2010-11-11 Novo Nordisk As Insulinderivate
WO2007104736A2 (en) * 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
EP2015722B1 (en) 2006-04-28 2016-11-16 Avent, Inc. Antimicrobial site dressings
CN101437849B (zh) * 2006-05-09 2015-09-30 诺沃-诺迪斯克有限公司 胰岛素衍生物
WO2007128815A1 (en) 2006-05-09 2007-11-15 Novo Nordisk A/S Insulin derivative
KR101441444B1 (ko) * 2006-05-09 2014-09-18 노보 노르디스크 에이/에스 인슐린 유도체
JP5097900B2 (ja) * 2006-06-27 2012-12-12 独立行政法人物質・材料研究機構 有機酸又はこれらの誘導体の活性エステル体の製造方法
EP2049149B1 (en) 2006-07-31 2015-04-15 Novo Nordisk A/S Pegylated extended insulins
JP5864834B2 (ja) 2006-09-22 2016-02-17 ノボ・ノルデイスク・エー／エス プロテアーゼ耐性のインスリンアナログ
US9387176B2 (en) 2007-04-30 2016-07-12 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
WO2008145728A1 (en) 2007-06-01 2008-12-04 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
US20100190706A1 (en) * 2007-06-01 2010-07-29 Novo Nordisk A/S Stable Non-Aqueous Pharmaceutical Compositions
JP5552046B2 (ja) * 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
KR20100053561A (ko) * 2007-08-15 2010-05-20 노보 노르디스크 에이/에스 아실 및 알킬렌 글리콜 부분을 갖는 인슐린 유사체
JP5721432B2 (ja) * 2007-08-15 2015-05-20 ノボ・ノルデイスク・エー／エス アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン
CN101157725B (zh) * 2007-10-24 2012-07-25 中国药科大学 人胰岛素类似物的制备方法及用途
ES2543393T3 (es) * 2007-11-08 2015-08-18 Novo Nordisk A/S Derivado de insulina
JP5241849B2 (ja) 2007-11-16 2013-07-17 ノボ・ノルデイスク・エー／エス インスリン及びインスリン分泌性ペプチドを含む薬学的組成物
JP5762001B2 (ja) 2008-03-14 2015-08-12 ノボ・ノルデイスク・エー／エス プロテアーゼ安定化インスリンアナログ
PT2254906T (pt) 2008-03-18 2017-01-03 Novo Nordisk As Análogos de insulina acilados, estabilizados contra proteases
US8637647B2 (en) 2008-09-12 2014-01-28 Novo Nordisk A/S Method of acylating a peptide or protein
US9603904B2 (en) * 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
MX2011007544A (es) 2009-01-23 2011-08-12 Novo Nordisk As Derivados de factor de crecimiento de fibroblastos 21 (fgf21) con ligante de albumina a-b-c-d-e- y su uso.
EP2493919A1 (en) 2009-10-30 2012-09-05 Novo Nordisk A/S Derivatives of cgrp
CN102753150A (zh) * 2010-01-12 2012-10-24 诺沃—诺迪斯克有限公司 用于口服给予胰岛素肽的药物组合物
EP2536752B1 (en) 2010-02-16 2015-04-08 Novo Nordisk A/S Modified recombinant Factor VIII
ES2582590T3 (es) 2010-02-16 2016-09-13 Novo Nordisk A/S Método de purificación
WO2011141407A1 (en) 2010-05-10 2011-11-17 Novo Nordisk A/S Process for the preparation of insulin-zinc complexes
EP2576612A4 (en) 2010-05-25 2014-07-09 Syngene Ltd INSULIN ANALOG
KR20130036290A (ko) 2010-06-23 2013-04-11 노보 노르디스크 에이/에스 추가 이황화 결합을 함유하는 인슐린 유도체
EP2585484A1 (en) 2010-06-23 2013-05-01 Novo Nordisk A/S Insulin analogues containing additional disulfide bonds
WO2011161083A1 (en) 2010-06-23 2011-12-29 Novo Nordisk A/S Human insulin containing additional disulfide bonds
EP2627670A2 (en) 2010-10-15 2013-08-21 Novo Nordisk A/S Novel n-terminally modified insulin derivatives
RU2013123515A (ru) * 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
CA2815419A1 (en) 2010-10-27 2012-05-03 Novo Nordisk A/S Treating diabetes melitus using insulin injections administered with varying injection intervals
WO2012080320A1 (en) 2010-12-14 2012-06-21 Novo Nordisk A/S Fast-acting insulin in combination with long-acting insulin
EP2675470A1 (en) 2011-02-15 2013-12-25 Novo Nordisk A/S Long-acting il-1 receptor antagonists
CN103596583B (zh) * 2011-03-28 2016-07-27 诺沃—诺迪斯克有限公司 新型胰高血糖素类似物
JP6030630B2 (ja) 2011-04-14 2016-11-24 ノヴォ ノルディスク アー／エス 経口ペプチド送達のための脂肪酸アシル化アミノ酸
WO2012171994A1 (en) 2011-06-15 2012-12-20 Novo Nordisk A/S Multi substituted insulins
IN2014CN02448A (hr) * 2011-09-23 2015-06-19 Novo Nordisk As
JP6153206B2 (ja) * 2011-12-15 2017-06-28 シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． ヒト・インスリン類似体及びそのアシル化誘導体
JP2015502971A (ja) 2011-12-21 2015-01-29 ノヴォ ノルディスク アー／エス Ｎ末端修飾インスリン誘導体
CA2870313A1 (en) 2012-04-11 2013-10-17 Novo Nordisk A/S Insulin formulations
US20160031962A1 (en) * 2012-04-20 2016-02-04 Kleomenis K. Barlos Solid phase peptide synthesis of insulin using side chain achored lysine
MX363119B (es) 2012-05-01 2019-03-11 Novo Nordisk As Composicion farmaceutica.
WO2014009316A1 (en) 2012-07-09 2014-01-16 Novo Nordisk A/S Novel use of insulin derivatives
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
CN104884078B (zh) 2012-10-17 2017-06-20 诺和诺德股份有限公司 用于口服肽递送的脂肪酸酰化d‑氨基酸
CN104870009B (zh) 2012-12-21 2021-05-18 赛诺菲 官能化的毒蜥外泌肽-4衍生物
JP6755175B2 (ja) * 2013-03-20 2020-09-16 ノヴォ ノルディスク アー／エス インスリン投薬レジメン
MX362275B (es) 2013-04-18 2019-01-10 Novo Nordisk As Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico.
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
AU2014333979B2 (en) 2013-10-07 2018-02-15 Novo Nordisk A/S Novel derivative of an insulin analogue
FR3013049B1 (fr) 2013-11-14 2015-11-13 You-Ping Chan Analogue de l'insuline glargine
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
MX2016010599A (es) 2014-02-18 2016-11-18 Novo Nordisk As Analogos de glucagon estables y uso para el tratamiento de hipoglucemia.
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
CN106536547A (zh) 2014-06-04 2017-03-22 诺和诺德股份有限公司 用于医疗用途的glp‑1/胰高血糖素受体共激动剂
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
CN108026156A (zh) 2015-08-25 2018-05-11 诺和诺德股份有限公司 新型胰岛素衍生物及其医学用途
WO2017032797A1 (en) 2015-08-25 2017-03-02 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
CN114478747B (zh) 2016-08-02 2024-06-14 江苏恒瑞医药股份有限公司 一种人胰岛素或其类似物的酰化衍生物
JP2019535791A (ja) 2016-11-28 2019-12-12 ノヴォ ノルディスク アー／エス 血糖コントロールの改善並びに急性及び長期糖尿病合併症の低減のためのインスリンデグルデク
WO2018096164A1 (en) 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for treating diabetes
EP3544683A1 (en) 2016-11-28 2019-10-02 Novo Nordisk A/S Insulin degludec in cardiovascular conditions
CN110087674B (zh) 2016-12-16 2023-01-03 诺和诺德股份有限公司 含胰岛素的药物组合物
JOP20190273A1 (ar) 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
RU2020128190A (ru) 2018-02-09 2022-03-09 Цзянсу Хэнжуй Медицин Ко., Лтд. Кодон-оптимизированный ген предшественника и ген сигнального пептида аналога человеческого инсулина
JP2021524464A (ja) 2018-05-24 2021-09-13 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Ｊｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．， Ｌｔｄ． 組換えヒトインスリンまたはそのアナログの前駆体の調製方法
WO2020002428A1 (en) 2018-06-26 2020-01-02 Novo Nordisk A/S System providing dose recommendations for basal insulin titration
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
KR102666154B1 (ko) 2018-08-08 2024-05-20 주식회사 대웅제약 지속형 인슐린 아날로그 및 그 복합체
KR20200080747A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법
KR20200080748A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법
AU2020321977C1 (en) 2019-07-31 2024-04-18 Eli Lilly And Company Relaxin analogs and methods of using the same
KR20220121833A (ko) 2019-12-30 2022-09-01 간 앤 리 파마슈티칼스 컴퍼니, 리미티드 인슐린 유도체
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
WO2023084118A1 (en) 2021-11-15 2023-05-19 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299071A1 (en) 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1212679B (de) 1957-08-03 1966-03-17 Novo Terapeutisk Labor As Verfahren zur Herstellung von Insulinloesungen
GB1042194A (en) 1962-04-30 1966-09-14 Olin Mathieson Insulin preparations
US3528960A (en) 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3868358A (en) 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
GB1492997A (en) 1976-07-21 1977-11-23 Nat Res Dev Insulin derivatives
JPS5767548A (en) 1980-10-14 1982-04-24 Shionogi & Co Ltd Insulin analog and its preparation
FI78616C (fi) 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
DE3827533A1 (de) 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
AU641631B2 (en) 1988-12-23 1993-09-30 Novo Nordisk A/S Human insulin analogues
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
JP3122128B2 (ja) 1989-12-21 2001-01-09 ノボ ノルディスク アクティーゼルスカブ ペプチド製剤
DK45590D0 (hr) 1990-02-21 1990-02-21 Novo Nordisk As
JP3193398B2 (ja) 1991-07-23 2001-07-30 サンデン株式会社 ショ−ケ−ス
RO111990B1 (ro) 1991-12-20 1997-04-30 Novo Nordisk As Preparate farmaceutice, continand un hormon de crestere sau un derivat al acestuia, si procedeu de preparare
WO1995007931A1 (en) * 1993-09-17 1995-03-23 Novo Nordisk A/S Acylated insulin
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US5652216A (en) 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
WO1996010417A1 (en) 1994-10-04 1996-04-11 Novo Nordisk A/S PREPARATIONS CONTAINING AspB28 HUMAN INSULIN AND NICOTINAMIDE
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5830999A (en) 1995-01-26 1998-11-03 Regents Of The University Of California Stabilization of insulin through ligand binding interations
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
CN1196061A (zh) 1995-03-17 1998-10-14 诺沃挪第克公司 胰岛素衍生物
AU716785B2 (en) 1995-07-27 2000-03-09 Genentech Inc. Stabile isotonic lyophilized protein formulation
US6451970B1 (en) * 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
US5898267A (en) * 1996-04-10 1999-04-27 Mcdermott; Kevin Parabolic axial lighting device
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
EP0938502B1 (en) 1996-07-11 2004-10-06 Novo Nordisk A/S Selective acylation method
US5905140A (en) 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
DK0821006T3 (da) 1996-07-26 2004-08-16 Aventis Pharma Gmbh Insulinderivater med öget zinkbinding
IL119029A0 (en) 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
ATE220555T1 (de) 1997-03-20 2002-08-15 Novo Nordisk As Verfahren zur herstellung eines therapeutischen puders durch copräzipitation von insulin und einem absorptionsverstärker
AU6611998A (en) 1997-03-20 1998-10-20 Novo Nordisk A/S Therapeutic powder formulation for pulmonary administration, containing crystalline insulin
HUP0000547A3 (en) * 1997-03-20 2002-11-28 Novo Nordisk As Zinc free insulin crystals for use in pulmonary compositions
US7097845B2 (en) 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
DK1283051T3 (da) 1997-06-13 2006-10-16 Lilly Co Eli Stabile insulinformuleringer
US20020155994A1 (en) 1997-10-24 2002-10-24 Svend Havelund Aggregates of human insulin derivatives
US6451762B1 (en) 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
HUP0004096A3 (en) * 1997-10-24 2001-12-28 Novo Nordisk As Aggregates of human insulin derivatives and pharmaceutical compositions comprising thereof
JP2001521006A (ja) 1997-10-24 2001-11-06 イーライ・リリー・アンド・カンパニー 不溶性インシュリン組成物
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
US6531448B1 (en) 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
AU1870099A (en) 1998-01-09 1999-07-26 Novo Nordisk A/S Stabilised insulin compositions
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
DE69920767T2 (de) 1998-10-16 2006-02-02 Novo Nordisk A/S Stabile konzentrierte Insulin Präparationen zur pulmonaren Verabreichung
DE60035260T2 (de) 1999-02-22 2007-10-18 The University Of Connecticut, Farmington Neue albuminfreie faktor viii formulierungen
EP1173482A1 (en) 1999-04-27 2002-01-23 Eli Lilly And Company Insulin crystals for pulmonary administration
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
ES2298378T3 (es) 2001-06-28 2008-05-16 Novo Nordisk A/S Formulacion estable de glp-1 modificado.
KR20040070237A (ko) 2001-12-20 2004-08-06 일라이 릴리 앤드 캄파니 연장된 작용 시간을 갖는 인슐린 분자
WO2003075950A1 (en) 2002-03-13 2003-09-18 Novo Nordisk A/S Minimising body weight gain in insulin treatment
ES2360182T3 (es) 2002-05-07 2011-06-01 Novo Nordisk A/S Formulaciones solubles que comprenden insulina monomérica e insulina acilada.
US20050232899A1 (en) 2002-05-31 2005-10-20 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US20040002451A1 (en) 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
KR100615389B1 (ko) 2002-08-23 2006-08-25 (주)헬릭서 다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품
RU2329823C2 (ru) 2002-10-29 2008-07-27 Алза Корпорейшн Стабилизированные твердые полипептидные частицы
US20040138099A1 (en) 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
AU2004210268B8 (en) 2003-02-07 2009-06-04 Ajinomoto Co., Inc. Therapeutic agents for diabetes
JP2007523836A (ja) 2003-02-19 2007-08-23 ノバルティス アクチエンゲゼルシャフト 転移ヒト腫瘍細胞で発現される糖タンパク質抗原ｓｉｍａ１３５
WO2004078196A1 (en) 2003-03-04 2004-09-16 The Technology Development Company Ltd. Oral insulin composition and methods of making and using thereof
JP4658041B2 (ja) 2003-06-25 2011-03-23 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドの液体組成物
US20050054818A1 (en) 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
EP2264065B1 (en) * 2003-08-05 2017-03-08 Novo Nordisk A/S Novel insulin derivatives
RU2352581C2 (ru) 2003-08-05 2009-04-20 Ново Нордиск А/С Производные инсулина
EP1656158B1 (en) 2003-08-14 2016-03-09 Novo Nordisk Health Care AG Liquid, aqueous pharmaceutical composition of factor vii polypeptides
JP5518282B2 (ja) 2003-09-01 2014-06-11 ノヴォ ノルディスク アー／エス 安定なペプチドの製剤
ES2229931B1 (es) 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
JP2007532096A (ja) 2003-11-14 2007-11-15 ノボ　ノルディスク　アクティーゼルスカブ アシル化されたインスリンの製造方法
CA2551510C (en) 2003-12-23 2013-07-30 Pharmacia Corporation Stable growth hormone liquid formulation
US7279457B2 (en) 2004-03-12 2007-10-09 Biodel, Inc. Rapid acting drug delivery compositions
WO2005117948A1 (en) 2004-06-01 2005-12-15 Ares Trading S.A. Method of stabilizing proteins
DE602005022895D1 (de) 2004-08-12 2010-09-23 Schering Corp Stabile pegylierte interferon-formulierung
AU2005277357B2 (en) 2004-08-17 2011-08-04 Regeneron Pharmaceuticals, Inc. IL-1 antagonist formulations
EP1814581B1 (en) 2004-11-12 2016-03-16 Novo Nordisk A/S Stable formulations of peptides comprising an acylated glp-1 analogue and a basal insuline
US8263551B2 (en) 2004-11-22 2012-09-11 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
JP2008528509A (ja) 2005-01-21 2008-07-31 アルザ コーポレイション 少なくとも１つの対イオンを含む、向上した安定性でマイクロニードルをコーティングするための治療用ペプチド製剤
EP2256130B1 (en) * 2005-02-02 2013-09-25 Novo Nordisk A/S Novel insulin derivatives
CN101389650B (zh) 2005-12-28 2012-10-10 诺沃-诺迪斯克有限公司 包含酰化胰岛素和锌的组合物以及制备所述组合物的方法
DE602007009496D1 (de) 2006-02-27 2010-11-11 Novo Nordisk As Insulinderivate
JP2009533471A (ja) 2006-04-12 2009-09-17 バイオデル， インコーポレイテッド 即効型および長時間作用型組合せインスリン製剤
KR101441444B1 (ko) 2006-05-09 2014-09-18 노보 노르디스크 에이/에스 인슐린 유도체
JP5552046B2 (ja) 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
JP5241849B2 (ja) 2007-11-16 2013-07-17 ノボ・ノルデイスク・エー／エス インスリン及びインスリン分泌性ペプチドを含む薬学的組成物
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物

Also Published As

Publication number Publication date
EP2107069A3 (en) 2009-11-25
LU92226I2 (fr) 2015-04-29
KR20060132543A (ko) 2006-12-21
AU2004261353A1 (en) 2005-02-10
US20100009899A1 (en) 2010-01-14
US8828923B2 (en) 2014-09-09
BRPI0413276B1 (pt) 2020-03-03
EP2107069A2 (en) 2009-10-07
HUS1300033I1 (hu) 2016-08-29
IL172980A0 (en) 2006-06-11
KR101159559B1 (ko) 2012-06-26
PL2107069T3 (pl) 2013-06-28
EP2264065B1 (en) 2017-03-08
EP1660531A2 (en) 2006-05-31
EP2264065A2 (en) 2010-12-22
NO2018003I1 (no) 2018-01-11
EP2107069B1 (en) 2013-01-16
AU2010200497A1 (en) 2010-03-04
AU2004261353B2 (en) 2009-12-10
BE2013C035I2 (hr) 2023-12-14
BE2013C038I2 (hr) 2023-12-14
US20140349925A1 (en) 2014-11-27
BRPI0413276B8 (pt) 2021-05-25
CY2013027I2 (el) 2015-11-04
FR13C0038I1 (fr) 2013-08-09
CY2013029I2 (el) 2015-11-04
CA2531988A1 (en) 2005-02-10
CY2013029I1 (el) 2015-11-04
EP2264065A3 (en) 2011-07-27
NO340925B1 (no) 2017-07-17
NO2018002I1 (no) 2018-01-11
CY2013027I1 (el) 2015-11-04
WO2005012347A3 (en) 2005-04-14
US7615532B2 (en) 2009-11-10
LU92213I2 (fr) 2013-08-23
CA2531988C (en) 2016-06-28
RU2518460C2 (ru) 2014-06-10
JP2007523881A (ja) 2007-08-23
NO2018002I2 (no) 2018-08-20
US20060183668A1 (en) 2006-08-17
LU92213I9 (hr) 2018-11-19
AU2010200497B2 (en) 2014-10-23
JP4463814B2 (ja) 2010-05-19
NO20061026L (no) 2006-03-02
CY1113850T1 (el) 2015-11-04
BRPI0413276A (pt) 2006-10-10
IL172980A (en) 2013-10-31
WO2005012347A2 (en) 2005-02-10
MXPA06001283A (es) 2006-04-11
RU2008152033A (ru) 2010-07-10
FR13C0035I2 (fr) 2014-03-07
LU92226I9 (hr) 2018-11-19

Similar Documents

Publication Publication Date Title
BE2015C007I2 (hr)
BE2014C055I2 (hr)
BE2014C027I2 (hr)
BE2014C003I2 (hr)
BE2013C075I2 (hr)
BE2013C069I2 (hr)
BE2013C067I2 (hr)
FR13C0035I1 (hr)
BE2013C036I2 (hr)
JP2004080992A5 (hr)
JP2004134051A5 (hr)
BE2015C005I2 (hr)
JP2004044803A5 (hr)
JP2003329713A5 (hr)
JP2004101514A5 (hr)
BE2012C053I2 (hr)
JP2004003075A5 (hr)
IN2006CH02600A (hr)
JP2004136363A5 (hr)
JP2004007401A5 (hr)
JP2004124696A5 (hr)
DE50310392D1 (hr)
JP2004154772A5 (hr)
JP2004092902A5 (hr)
JP2004118176A5 (hr)